361 Capital’s Molecular Templates, Inc. MTEM Stock Holding History

361 Capital’s Portfolio MTEM Stock Details MTEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,207	Closed	-$639K	–	398
2020 Q1	$639K	Buy	+3,207	New	+$702K	0.29%	181

Other funds holding MTEM

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

361 Capital's MTEM Position: Q2 2020 in Review

361 Capital sold out of Molecular Templates, Inc. (MTEM) in Q2 2020, closing a stake of 3,207 shares — an estimated $639K sold.

361 Capital first reported a position in MTEM in Q1 2020 and held it in 1 quarter. The position peaked at $639K in Q1 2020. 102 funds tracked by Wall St. Rank hold MTEM as of Q2 2020.

361 Capital reported no remaining Molecular Templates, Inc. position as of Q2 2020 after selling out during the quarter.
361 Capital sold 3,207 Molecular Templates, Inc. shares in Q2 2020, an estimated $639K.
361 Capital first reported a position in Molecular Templates, Inc. in Q1 2020 and held it in 1 quarter.
361 Capital's Molecular Templates, Inc. position peaked at $639K in Q1 2020.
102 funds tracked by Wall St. Rank held Molecular Templates, Inc. as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.